CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, announced that it has reached an agreement to settle its consolidated stockholder derivative lawsuit, In Re CytRx Corporation Stockholder Derivative Litigation, pending in the U.S. Court of Appeals for the Ninth Circuit Court (Case No. 15-56773), on appeal from the United States District Court for the Central District of California (Case No. CV 14-6414-GHK (PJWx)).

The settlement includes no financial or equity compensation.  It provides that CytRx will implement certain corporate governance changes and modify certain governance practices, many of which have already been implemented over the past 12 months.

The lawsuit names as defendants certain current and former directors and officers, and names the Company as a nominal defendant, and relates to the Company’s hiring of an external investor and public relations firm in parts of 2013 and 2014.  Although the individual defendants continue to deny any liability or wrongdoing in connection with the allegations in the lawsuit, and the settlement agreement contains no admission of liability or wrongdoing and includes a full release of the current and former directors and officers in connection with the allegations, the individual defendants believe it is in the best interests of CytRx and its stockholders to settle the matter on reasonable terms to avoid potentially lengthy and costly litigation.

“With this settlement, we can continue to focus on our pre-commercial activities for aldoxorubicin, the development of aldoxorubicin and DK049, and the creation of new molecules using our LADRTM technology,” said Steven A. Kriegsman, Chairman and CEO.

The parties have not yet reached an agreement on an amount of fees and expenses to the plaintiffs’ attorneys, but the settlement is not dependent on such agreement or the amount of any fees and expenses approved by the Court.  The settlement is subject to approval by the Court and certain other conditions, including notice to the Company’s stockholders. (Original Source)

Shares of Cytrx closed yesterday at $2.56, down $0.09 or -3.40%. CYTR has a 1-year high of $5.42 and a 1-year low of $1.98. The stock’s 50-day moving average is $2.86 and its 200-day moving average is $2.90.

On the ratings front, Oppenheimer analyst Christopher Marai reiterated a Buy rating on CYTR, with a price target of $10, in a report issued on November 5. The current price target implies an upside of 290.6% from current levels.

According to, Marai has a total average return of 25.4%, a 65.2% success rate, and is ranked #8 out of 3648 analysts.

CytRx Corp is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes three clinical-stage drug candidates in various stages of development: Aldoxorubicin, Tamibarotene, and Bafetinib.